NEW YORK (TheStreet) -- Say what you want about Wall Street's "unpredictability," but when investors' minds are made up about a company, there's often little that can change that sentiment. It goes both ways. If you're on the Street's good side -- like St. Jude Medical (STJ - Get Report) appears to be -- it's a great position to be in. Or is it?
While St. Jude has enjoyed years of solid performances in the medical devices industry against rivals like Johnson & Johnson (JNJ) and Medtronic (MDT), its execution has been anything but flawless. St. Jude's Riata and Durata leads, made to help prevent heart failures, have been failing, thus hurting the company's reputation.
These at-home leads should help carry electrical impulses to the heart and provide information from the heart back to the devices. However, overwhelming reports of malfunctions due to premature insulation failure not only resulted in product recalls, but also generated class-action claims.
Making the situation even more dreadful, the company is now operating under several written warnings from the Food and Drug Administration. On top of that, there are now worries about the company's product pipeline, which lacks the growth potential of Medtronic.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts